FilingReader Intelligence
Gentian Diagnostics reports 14% Q2 sales growth
July 17, 2025 at 03:34 PM UTC•By FilingReader AI
Gentian Diagnostics reported Q2 2025 sales of NOK 43.6 million, up 14% year-over-year, with first-half revenue rising 15% to NOK 88.1 million.
Cystatin C sales surged 31% in Q2, with 156% US growth and 31 new customer additions. Gross margin fell to 44% from 57% due to raw material issues, though first-half EBITDA improved to NOK 15.7 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
OSL:GENT•Oslo Stock Exchange
News Alerts
Get instant email alerts when Gentian Diagnostics ASA publishes news
Free account required • Unsubscribe anytime